



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/506746
				Filing Date	September 3, 2004
				First Named Inventor	Paul Whittamore
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-667

SC	BZ	EP-1145717	05-12-2004	Pfizer Products Inc.		
	BA1	EP-1149580	02-21-2001	Pfizer Products Inc.		
	BB1	EP-1177791	07-27-2001	Pfizer Products Inc.		
	BC1	ES-2081747	03-01-1996	Esteve Labor DR		
	BD1	DE-4445968	06-27-1996	Bayer AG		
	BE1	WO-93/25574	12-23-1993	Pfizer Inc.		
	BF1	WO-95/24391	09-14-1995	Novo Nordisk		
	BG1	WO-96/39384	12-12-1996	Pfizer, Inc.		
	BH1	WO-96/39385	12-12-1996	Pfizer Inc.		
	BI1	WO-97/09040	03-13-1997	Novo Nordisk		
	BJ1	WO-97/31901	09-04-1997	Mikael Bols		
	BK1	WO-97/45425	12-04-1997	Fujisawa Pharmaceutical Co., Ltd.		
	BL1	WO-98/27108	06-25-1998	Fuji-Sawa Pharmaceutical Co., Ltd.		
	BM1	WO-98/40353	09-17-1998	Novo Nordisk		
	BN1	WO-98/50359	11-12-1998	Novo Nordisk		
	BO1	WO-99/26659	06-03-1999	Pfizer Products Inc.		
	BP1	WO-99/36393	07-22-1999	Tanabe Seiyaku Co., Ltd.		
	BQ1	JP 2001 089368	4/30/01			
	BR1	DD 200740	06-08-1983	Gewald		
	BS1	EP 697403	02-21-1996	Sanofi		
	BT1	JP 2001 206856	07-31-2001	Pfizer Prod. Inc.		
	BU1	JP 021247565	05-14-1990	Hanawa Netsuden Kinzoku KK		
				Toray Ind. Inc.		
	BV1	JP 04179949	06-26-1992			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
SC	CA	Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, AstraZeneca UK, CVGI Research, Mereside, Alderley Park, Macclesfield, Cheshire.		
	CB	Crochet, R.A., et al., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).		
	CC	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 1470-P, A340.		
	CD	Hartman, G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 29(10):1943-1949 (1989).		
	CE	Hoover, D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 41:2934-2938 (1998).		
	CF	Hudson, S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 539:52-53 (2002).		
	CG	Jakobsen, P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase,"		
Examiner Signature	Susannah Chung		Date Considered	12/27/05